Method of treating an anxiety disorder

1. A method of treating an anxiety disorder, comprising administering to a patient in need thereof an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof in combination with alprazolam.

2. The method according to claim 1 , wherein the anxiety disorder is panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder or specific phobia.

3. The method according to claim 1 , wherein the anxiety disorder is panic disorder, agoraphobia, generalized anxiety disorder or specific phobia.

4. The method according to claim 1 , wherein said (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or pharmaceutically acceptable salt thereof is administered in an amount of from 0.001 to 20.0 mg/kg body weight.

5. The method according to claim 4 , wherein said pharmaceutically acceptable salt is an acid addition salt, a metal salt, an ammonium salt, an organic amine addition salt or an amino acid addition salt.

6. The method according to claim 5 , wherein said (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or pharmaceutically acceptable salt thereof is administered in an amount of from 0.01 to 10 mg/kg body weight.

7. The method according to claim 6 , wherein said pharmaceutically acceptable salt is an inorganic acid addition salt.

8. The method according to claim 7 , wherein said pharmaceutically acceptable salt is a hydrochloride, sulfate, nitrate or phosphate salt.

9. The method according to claim 6 , wherein said pharmaceutically acceptable salt is an organic acid addition salt.

10. The method according to claim 9 , wherein said pharmaceutically acceptable salt is an acetate, maleate, fumarate or citrate sale.

11. The method according to claim 6 , wherein said pharmaceutically acceptable salt is a metal salt.

12. The method according to claim 11 , wherein said pharmaceutically acceptable salt is an alkali metal salt.

13. The method according to claim 12 , wherein said pharmaceutically acceptable salt is a sodium salt or potassium salt.

14. The method according to claim 11 , wherein said pharmaceutically acceptable salt is an alkaline earth metal salt.

15. The method according to claim 14 , wherein said pharmaceutically acceptable salt is a magnesium or calcium salt.

16. The method according to claim 11 , wherein said pharmaceutically acceptable salt is an aluminum or zinc salt.

17. The method according to claim 6 , wherein said pharmaceutically acceptable salt is an ammonium or tetramethylammonium salt.

18. The method according to claim 6 , wherein said pharmaceutically acceptable salt is said organic amine addition salt.

19. The method according to claim 18 , wherein said pharmaceutically acceptable salt is an addition salt with morpholine or piperidine.

20. The method according to claim 6 , wherein said pharmaceutically acceptable salt is said amino acid addition salt.

21. The method according to claim 20 , wherein said pharmaceutically acceptable salt is an addition salt with lysine, glycine or phenylalanine.

22. The method of treating an anxiety disorder according to claim 1 , wherein the anxiety disorder is panic disorder.

23. The method of treating an anxiety disorder according to claim 1 , wherein the anxiety disorder is agoraphobia.

24. The method of treating an anxiety disorder according to claim 1 , wherein the anxiety disorder is obsessive-compulsive disorder.

25. The method of treating an anxiety disorder according to claim 1 , wherein the anxiety disorder is social phobia.

26. The method of treating an anxiety disorder according to claim 1 , wherein the anxiety disorder is post-traumatic stress disorder.

27. The method of treating an anxiety disorder according to claim 1 , wherein the anxiety disorder is specific phobia.

28. The method of treating an anxiety disorder according to claim 1 , wherein the anxiety disorder is generalized anxiety disorder.